4//SEC Filing
Aeglea BioTherapeutics, Inc. 4
Accession 0001140361-16-060935
$SYRECIK 0001636282operating
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 5:13 PM ET
Size
9.1 KB
Accession
0001140361-16-060935
Insider Transaction Report
Form 4
TYLER JOSEPH E
VP, Manufacturing
Transactions
- Conversion
Common Stock
2016-04-12+31,260→ 42,428 total - Conversion
Series A Preferred Stock
2016-04-12−22,857→ 0 totalExercise: $0.00→ Common Stock (22,857 underlying) - Conversion
Series B Preferred Stock
2016-04-12−8,403→ 0 totalExercise: $0.00→ Common Stock (8,403 underlying)
Footnotes (1)
- [F1]In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
Documents
Issuer
Aeglea BioTherapeutics, Inc.
CIK 0001636282
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001636282
Filing Metadata
- Form type
- 4
- Filed
- Apr 11, 8:00 PM ET
- Accepted
- Apr 12, 5:13 PM ET
- Size
- 9.1 KB